Medpace Holdings, Inc. Increase (Decrease) in Contract with Customer, Liability
Medpace Holdings, Inc. (MEDP) reported Increase (Decrease) in Contract with Customer, Liability of $50.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-23
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $48.38M, a 46.29% decline year-over-year.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $1.95M, a 75.97% decline year-over-year.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $20.06M, a 49.40% decline year-over-year.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $25.55M, a 21.45% decline year-over-year.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was $143.81M, a 4.59% decline from fiscal 2024.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $150.72M, a 55.18% increase from fiscal 2023.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $97.13M, a 17.75% decline from fiscal 2022.
- Medpace Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $118.09M, a 32.72% increase from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $50.33M 10-Q · filed 2026-07-23 | $70.39M derived: sum of 3 quarters · filed 2026-07-23 | $95.94M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $1.95M 10-Q · filed 2026-04-23 | $22.02M derived: sum of 2 quarters · filed 2026-04-23 | $47.56M derived: sum of 3 quarters · filed 2026-04-23 | $137.63M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $20.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $45.61M derived: sum of 2 quarters · filed 2026-02-10 | $135.67M derived: sum of 3 quarters · filed 2026-07-23 | $143.81M 10-K · filed 2026-02-10 |
| 2025-09-30 | $25.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $115.61M derived: sum of 2 quarters · filed 2026-07-23 | $123.74M 10-Q · filed 2025-10-23 | $163.39M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $90.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $98.20M 10-Q · filed 2026-07-23 | $137.84M derived: sum of 3 quarters · filed 2026-07-23 | $170.37M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $8.13M 10-Q · filed 2026-04-23 | $47.78M derived: sum of 2 quarters · filed 2026-04-23 | $80.30M derived: sum of 3 quarters · filed 2026-04-23 | $102.02M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $39.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $72.17M derived: sum of 2 quarters · filed 2026-02-10 | $93.89M derived: sum of 3 quarters · filed 2026-02-10 | $150.72M 10-K · filed 2026-02-10 |
| 2024-09-30 | $32.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $54.24M derived: sum of 2 quarters · filed 2025-10-23 | $111.08M 10-Q · filed 2025-10-23 | $152.18M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $21.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $78.56M 10-Q · filed 2025-07-22 | $119.66M derived: sum of 3 quarters · filed 2026-02-10 | $147.86M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $56.84M 10-Q · filed 2025-04-22 | $97.94M derived: sum of 2 quarters · filed 2026-02-10 | $126.14M derived: sum of 3 quarters · filed 2026-02-10 | $150.66M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $41.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $69.30M derived: sum of 2 quarters · filed 2026-02-10 | $93.82M derived: sum of 3 quarters · filed 2026-02-10 | $97.13M 10-K · filed 2026-02-10 |
| 2023-09-30 | $28.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $52.72M derived: sum of 2 quarters · filed 2024-10-22 | $56.03M 10-Q · filed 2024-10-22 | $100.83M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $24.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $27.83M 10-Q · filed 2024-07-23 | $72.63M derived: sum of 3 quarters · filed 2025-02-11 | $89.19M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $3.31M 10-Q · filed 2024-04-23 | $48.11M derived: sum of 2 quarters · filed 2025-02-11 | $64.67M derived: sum of 3 quarters · filed 2025-02-11 | $98.82M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $44.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $61.36M derived: sum of 2 quarters · filed 2025-02-11 | $95.51M derived: sum of 3 quarters · filed 2025-02-11 | $118.09M 10-K · filed 2025-02-11 |
| 2022-09-30 | $16.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | $50.71M derived: sum of 2 quarters · filed 2023-10-24 | $73.29M 10-Q · filed 2023-10-24 | $114.08M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $34.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $56.73M 10-Q · filed 2023-07-25 | $97.52M derived: sum of 3 quarters · filed 2024-02-13 | $119.15M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $22.58M 10-Q · filed 2023-04-25 | $63.37M derived: sum of 2 quarters · filed 2024-02-13 | $85.00M derived: sum of 3 quarters · filed 2024-02-13 | $89.41M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $40.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $62.42M derived: sum of 2 quarters · filed 2024-02-13 | $66.83M derived: sum of 3 quarters · filed 2024-02-13 | $88.98M 10-K · filed 2024-02-13 |
| 2021-09-30 | $21.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $26.04M derived: sum of 2 quarters · filed 2022-10-25 | $48.18M 10-Q · filed 2022-10-25 | $101.24M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-26 | $26.55M 10-Q · filed 2022-07-26 | $79.61M derived: sum of 3 quarters · filed 2023-02-14 | $86.87M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $22.14M 10-Q · filed 2022-04-26 | $75.19M derived: sum of 2 quarters · filed 2023-02-14 | $82.46M derived: sum of 3 quarters · filed 2023-02-14 | $88.25M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $53.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $60.31M derived: sum of 2 quarters · filed 2023-02-14 | $66.10M derived: sum of 3 quarters · filed 2023-02-14 | $63.41M 10-K · filed 2023-02-14 |
| 2020-09-30 | $7.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-26 | $13.05M derived: sum of 2 quarters · filed 2021-10-26 | $10.36M 10-Q · filed 2021-10-26 | $33.04M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $3.09M 10-Q · filed 2021-07-27 | $25.78M derived: sum of 3 quarters · filed 2022-02-15 | $30.13M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$2.69M 10-Q · filed 2021-04-27 | $19.99M derived: sum of 2 quarters · filed 2022-02-15 | $24.34M derived: sum of 3 quarters · filed 2022-02-15 | $39.45M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $22.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $27.04M derived: sum of 2 quarters · filed 2022-02-15 | $42.15M derived: sum of 3 quarters · filed 2022-02-15 | $44.58M 10-K · filed 2022-02-15 |
| 2019-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $19.46M derived: sum of 2 quarters · filed 2020-10-27 | $21.90M 10-Q · filed 2020-10-27 | $29.22M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $15.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | $17.55M 10-Q · filed 2020-07-28 | $24.86M derived: sum of 3 quarters · filed 2021-02-16 | $37.29M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $2.44M 10-Q · filed 2020-04-29 | $9.75M derived: sum of 2 quarters · filed 2021-02-16 | $22.18M derived: sum of 3 quarters · filed 2021-02-16 | $31.21M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $7.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $19.75M derived: sum of 2 quarters · filed 2021-02-16 | $28.78M derived: sum of 3 quarters · filed 2021-02-16 | $35.59M 10-K · filed 2021-02-16 |
| 2018-09-30 | $12.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $21.46M derived: sum of 2 quarters · filed 2019-10-29 | $28.28M 10-Q · filed 2019-10-29 | $33.63M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $9.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $15.85M 10-Q · filed 2019-07-30 | $21.20M derived: sum of 3 quarters · filed 2020-02-25 | $23.88M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $6.82M 10-Q · filed 2019-04-30 | $12.17M derived: sum of 2 quarters · filed 2020-02-25 | $14.85M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-31 | $5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $8.03M derived: sum of 2 quarters · filed 2020-02-25 | $7.74M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $2.38M 10-Q · filed 2018-10-30 | ||
| 2017-06-30 | -$294.00K 10-Q · filed 2018-07-31 | |||
| 2016-12-31 | $14.72M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |